Elastrin Therapeutics has developed a nanotechnology capable of reversing chronic cardiovascular and lung diseases by regenerating damaged elastin. Our lead compound will be in clinical trials next year in an orphan indication, and we have just received Rare Pediatric Disease Designation by the FDA. Our latest innovation is a therapeutic mRNA and has just started preclinical development.